文献速递青光眼

对于晚期原发性开角型青光眼患者,初次小梁切除术是否具有成本效益?来自晚期青光眼治疗研究经济模型的结果

Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model.
PubMed 文献 · Br J Ophthalmol · 2024-08-22

本研究基于晚期青光眼治疗研究(TAGS)数据构建马尔可夫模型,比较晚期原发性开角型青光眼(POAG)患者接受药物治疗与初次小梁切除术的成本和质量调整生命年(QALYs)。在终身时间范围和EQ-5D-5L测量下,小梁切除术平均增加成本£2687、增加0.28 QALYs,增量成本效果比为每QALY £9679;当社会支付意愿为每QALY £20000时,小梁切除术具有成本效益的概率为73%。结论认为小梁切除术在患者终身时间范围内较药物治疗有更高的成本效益概率。

要点

  • 在终身时间范围和EQ-5D-5L测量下,小梁切除术较药物治疗平均增加成本£2687、增加0.28 QALYs,增量成本效果比为每QALY £9679。
  • 当社会支付意愿为每QALY £20000时,小梁切除术具有成本效益的概率为73%。
  • 在2年时间范围内,小梁切除术较药物治疗的增量成本效果比为每QALY £47663。

核心结论

  • 在晚期POAG患者中,小梁切除术在患者终身时间范围内较药物治疗有更高的成本效益概率。

研究设计与样本

  • 采用马尔可夫模型比较药物治疗与小梁切除术治疗晚期POAG的成本和QALYs。
  • 模型数据来自晚期青光眼治疗研究(TAGS),并补充文献数据。
  • 采用概率敏感性分析和确定性分析评估模型发现的不确定性。
  • 主要结局基于EQ-5D-5L、Health Utilities Index-3和青光眼效用指数(Glaucoma Utility Index)的响应,以增量成本和QALYs表示。

主要发现

  • 在基础案例分析(终身时间范围和EQ-5D-5L测量)中,接受小梁切除术的参与者较药物治疗平均增加成本£2687、增加0.28 QALYs,增量成本效果比为每QALY £9679。
  • 当社会支付意愿为每QALY £20000时,小梁切除术具有成本效益的概率为73%。
  • 在较短时间范围(2年)内,小梁切除术较药物治疗的增量成本效果比为每QALY £47663。
  • 结果对关键假设和输入参数值的变化稳健。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: Advanced primary open angle glaucoma (POAG) is a lifelong condition. The aim of this study is to compare medical treatment against trabeculectomy for patients presenting with advanced POAG using an economic evaluation decision model. METHODS: A Markov model was used to compare the two treatments, medical treatment versus trabeculectomy for the management of advanced POAG, in terms of costs and quality-adjusted life-years (QALYs). The uncertainty surrounding the model findings was assessed using probabilistic sensitivity analysis and deterministic analysis. Data for the model came from Treatment of Advanced Glaucoma Study supplemented with data from the literature. The main outcomes of the model presented in terms of Incremental costs and QALYs based on responses to the EQ-5D-5L, Health Utilities Index-3 and a Glaucoma Utility Index. RESULTS: In the base-case analysis (lifetime horizon and EQ-5D-5L measure), participants receiving trabeculectomy had on average, an additional cost of £2687, an additional 0.28 QALYs and an incremental cost per QALY of £9679 compared with medical treatment. There was a 73% likelihood of trabeculectomy being considered cost-effective when society was willing to pay £20 000 for a QALY. Over shorter time horizons, the incremental cost per QALY gained from trabeculectomy compared with medical treatment was higher (47 663) for a 2-year time horizon. Our results are robust to changes in the key assumptions and input parameters values. CONCLUSION: In patients presenting with advanced POAG, trabeculectomy has a higher probability of being cost-effective over a patient's lifetime compared with medical treatment.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shabaninejad H, Homer T, Kernohan A, et al. Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model. Br J Ophthalmol. 2024. PMID: 38336459. doi:10.1136/bjo-2023-323390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。